ARIA
ARIAD Pharmaceuticals, Inc.NASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Tue, Nov. 29, 12:35 PM
    • The FDA grants full approval for ARIAD Pharmaceuticals' (ARIA +1.6%) Iclusig (ponatinib) for the treatment of adult patients with chronic phase, accelerated phase or blast phase chronic myeloid leukemia (CML) for whom no other TKI therapy is indicated and for the treatment of adult patients with T315I-positive CML or T315I-positive Ph+ acute lymphocytic leukemia.
    • The FDA initially OK'd Iclusig in December 2012 under its accelerated approval program.
    • The agency also approved an update to Iclusig's label to include 48-month follow-up data from the Phase 2 PACE study. The results confirmed the product's safety profile and long-term durability of response.
    • Enrollment is ongoing in a post-market dose-ranging study called OPTIC that will inform the optimal dosing of Iclusig. Top-line data will be submitted for presentation at next year's meeting of the American Society of Hematology (ASH).
    | Tue, Nov. 29, 12:35 PM | 1 Comment
  • Tue, Nov. 29, 9:22 AM
    | Tue, Nov. 29, 9:22 AM | 1 Comment
  • Thu, Nov. 10, 9:17 AM
    | Thu, Nov. 10, 9:17 AM
  • Wed, Nov. 9, 7:56 AM
    • In its 10-Q filed yesterday, ARIAD Pharmaceuticals (NASDAQ:ARIA) discloses (page 23) that it recently received a subpoena from the U.S. Attorney's Office for the District of Massachusetts requesting documentation related to its support of nonprofit organizations that provide financial help to Medicare patients and its own patient support programs. It adds that other companies in the industry have received similar inquiries and that it intends to cooperate fully.
    • The company also reports that, on November 4, it responded to an October letter from U.S. Rep. Elijah Cummings and Sen. Bernie Sanders requesting information related to the pricing of Iclusig in the U.S. including its rationale for pricing and commercialization.
    • Investors appear unconcerned. Shares are up 11% premarket on increased volume.
    | Wed, Nov. 9, 7:56 AM | 4 Comments
  • Mon, Nov. 7, 9:29 AM
    • ARIAD Pharmaceuticals (ARIA) Q3 results: Revenues: $46M (+58.1%); Operating Loss: ($25M) (+55.7%); Net Loss: ($27.8M) (+49.9%); Loss Per Share: ($0.14) (+51.7%); Non-GAAP Loss Per Share: ($0.12) (+50.0%); Quick Assets: $314.7M (+29.9%); CF Ops: ($121.4M) (-0.6%).
    • 2016 Guidance: Global Iclusig Net Product and Royalty Revenue: $170M - 180M; R&D Expense: $175M - 180M; SG&A Expense: $120M - 125M; cash, cash equivalents and marketable securities: $280M - 290M.
    | Mon, Nov. 7, 9:29 AM | 2 Comments
  • Mon, Nov. 7, 9:17 AM
    | Mon, Nov. 7, 9:17 AM | 4 Comments
  • Mon, Nov. 7, 7:36 AM
    • ARIAD Pharmaceuticals (NASDAQ:ARIA): Q3 EPS of -$0.12 beats by $0.07.
    • Revenue of $46.02M (+58.3% Y/Y) beats by $3.09M.
    • Press Release
    | Mon, Nov. 7, 7:36 AM | 12 Comments
  • Sun, Nov. 6, 5:30 PM
  • Fri, Nov. 4, 7:42 AM
    • Theravance Biopharma (NASDAQ:TBPH) initiated with Overweight rating and $42 (71% upside) price target by Piper Jaffray.
    • Viveve Medial (Pending:VIVE) initiated with Buy rating and $8 (59% upside) price target by B. Riley.
    • Alexion Pharmaceuticals (NASDAQ:ALXN) initiated with Buy rating and $164 (29% upside) price target by Deutsche Bank.
    • Halozyme Therapeutics (NASDAQ:HALO) initiated with Buy rating and $12 (42% upside) price target by Deutsche Bank.
    • Cynosure (NASDAQ:CYNO) initiated with Buy rating and $60 (47% upside) price target by Aegis Capital.
    • ARIAD Pharmaceuticals (NASDAQ:ARIA) initiated with Hold rating and $9.50 (10% upside) price target by Deutsche Bank.
    • Aurinia Pharmaceuticals (NASDAQ:AUPH) initiated with Speculative Buy rating and $8 (214% upside) price target by Mackie Research Capital.
    • Achaogen (NASDAQ:AKAO) initiated with Buy rating and $10 (166% upside) price target by Aegis Capital.
    • Kindred Biosciences (NASDAQ:KIN) initiated with Buy rating and $7.50 (46% upside) price target by Ladenburg Thalmann.
    • Global Blood Therapeutics (NASDAQ:GBT) initiated with Buy rating and $47 (210% upside) price target by Roth Capital.
    • Obalon Therapeutics (Pending:OBLN) initiated with Buy rating and $28 (207% upside) price target by Canaccord Genuity. Initiated with Buy rating and $18 (97% upside) price target by Stifel Nicolaus.
    | Fri, Nov. 4, 7:42 AM
  • Mon, Oct. 31, 8:01 AM
    • The FDA accepts for review ARIAD Pharmaceuticals' (NASDAQ:ARIA) New Drug Application (NDA) seeking approval of brigatinib for the treatment of patients with ALK-positive non-small cell lung cancer (NSCLC) who have progressed on crizotinib [Pfizer's (NYSE:PFE) XALKORI]. The agency's action date (PDUFA) is April 29, 2017 under Priority Review status.
    • The company expects to file its marketing application in Europe in Q1.
    • Brigatinib is an oral inhibitor of an enzyme called anaplastic lymphoma kinase (ALK). The abnormal expression of ALK is a key driver of certain types of non-small cell lung cancer, neuroblastomas and anaplastic large cell lymphoma. It is not generally expressed in normal adult tissues so it is a promising therapeutic target.
    • Shares are up 2% premarket on light volume.
    | Mon, Oct. 31, 8:01 AM | 4 Comments
  • Fri, Oct. 28, 1:02 PM
    • United Therapeutics (NASDAQ:UTHR) upgraded to Buy from Neutral by Ladenburg Thalmann. Price target raised to $138 (18% upside) from $128.
    • NeoGenomics (NASDAQ:NEO) upgraded to Buy from Neutral with a $10 (25% upside) price target by BTIG Research.
    • Pacira Pharmaceuticals (NASDAQ:PCRX) upgraded to Market Perform from Underperform by BMO Capital. Price target raised to $36 (8% upside) from $35.
    • Alkermes (NASDAQ:ALKS) upgraded to Overweight from Neutral by JPMorgan. Price target raised to $78 (53% upside) from $51.
    • McKesson (NYSE:MCK) downgraded to Neutral from Outperform by Baird. Price target lowered to $164 (34% upside) from $200. Also downgraded by Standpoint Research, Deutsche Bank and Leerink Swann.
    • Community Health Systems (NYSE:CYH) downgraded to Underperform from Neutral by Baird. Price target lowered to $8 (47% upside) from $12.
    • TeamHealth Holdings (NYSE:TMH) downgraded to Market Perform from Outperform by Leerink Swann. Price target raised to $43 (17% upside) from $40..
    • ARIAD Pharmaceuticals (NASDAQ:ARIA) downgraded to Market Perform from Market Outperform by JMP Securities. Price target raised to $9.37 (7% upside) from $4.37.
    • Vertex Pharmaceuticals (NASDAQ:VRTX) downgraded to Neutral from Buy by H.C. Wainwright. Price target lowered to $85 (8% upside) from $155.
    • Teva Pharmaceutical Industries (NASDAQ:TEVA) downgraded to Neutral from Buy by Mizuho. Price target lowered to $45 (7% upside) from $64.
    | Fri, Oct. 28, 1:02 PM | 5 Comments
  • Wed, Oct. 26, 9:12 AM
    | Wed, Oct. 26, 9:12 AM | 3 Comments
  • Mon, Oct. 17, 10:50 AM
    • Holders of ARIAD Pharmaceuticals (NASDAQ:ARIA) are taking a breather in early trading. Shares are up a fraction on slightly higher volume. On Friday afternoon, shares plunged 15% on more than triple normal volume in response to a tweet from Senator Bernie Sanders criticizing the company for its greed related to leukemia drug Iclusig (ponatinib). According to Bloomberg, it has raised the price four times in a year. A 30-day pack of the pill now costs more than $16,000 or almost $200K per annum.
    | Mon, Oct. 17, 10:50 AM | 8 Comments
  • Fri, Oct. 7, 11:48 AM
    • Lexicon Pharmaceuticals (NASDAQ:LXRX) initiated with Buy rating and $26 (38% upside) price target by H.C. Wainwright.
    • Zynerba Pharmaceuticals (NASDAQ:ZYNE) initiated with Buy rating and $22 (54% upside) price target by H.C. Wainwright.
    • Mazor Robotics (NASDAQ:MZOR) initiated with Buy rating and $25 (10% upside) price target by B. Riley.
    • Lipocine (NASDAQ:LPCN) initiated with Buy rating and $25 (350% upside) price target by H.C. Wainwright.
    • TG Therapeutics (NASDAQ:TGTX) initiated with Buy rating and $28 (218% upside) price target by Brean Capital.
    • Immunomedics (NASDAQ:IMMU) initiated with Buy rating and $5.50 (113% upside) price target by Jefferies.
    • AmerisourceBergen (NYSE:ABC) initiated with Neutral rating by UBS.
    • ARIAD Pharmaceuticals (NASDAQ:ARIA) initiated with Buy rating and $22 (65% upside) price target by SunTrust Robinson Humphrey.
    • Amarin (NASDAQ:AMRN) initiated with Buy rating and $6 (92% upside) price target by Cantor Fitzgerald.
    • Corbus Pharmaceuticals (NASDAQ:CRBP) initiated with Buy rating and $17 (94% upside) price target by Cantor Fitzgerald.
    • Heron Therapeutics (NASDAQ:HRTX) initiated with Buy rating and $41 (142% upside) price target by Brean Capital.
    • Zogenix (NASDAQ:ZGNX) initiated with Outperform rating and $17 (64% upside) price target by Leerink Swann.
    • GW Pharmaceuticals (NASDAQ:GWPH) initiated with Outperform rating and $162 (23% upside) price target by Leerink Swann. Initiated with Buy rating and $189 (44% upside) price target by Goldman Sachs.
    • SAGE Therapeutics (NASDAQ:SAGE) initiated with Outperform rating and $68 (57% upside) price target by Leerink Swann.
    • Alexion Pharmaceuticals (NASDAQ:ALXN) initiated with Buy rating and $221 (79% upside) price target by Brean Capital.
    • Axsome Therapeutics (NASDAQ:AXSM) initiated with Buy rating and $20 (136% upside) price target by Brean Capital.
    • Recro Pharma (NASDAQ:REPH) initiated with Buy rating and $21 (156% upside) price target by Brean Capital.
    • SCYNEXIS (NASDAQ:SCYX) initiated with Buy rating and $16 (226% upside) price target by Brean Capital.
    • Sorrento Therapeutics (NASDAQ:SRNE) initiated with Buy rating and $15 (94% upside) price target by Roth Capital.
    • Global Blood Therapeutics (NASDAQ:GBT) initiated with Outperform rating and a $75 - 81 (322% upside from midpoint) target price range by Wells Fargo.
    • Alder Biopharmaceuticals (NASDAQ:ALDR) initiated with Buy rating and $45 (49% upside) price target by Brean Capital.
    | Fri, Oct. 7, 11:48 AM | 8 Comments
  • Fri, Sep. 30, 7:54 AM
    • Zoetis (NYSE:ZTS) initiated wit Buy rating with a $60 (18% upside) price target by Bank of America.
    • Akebia Therapeutics (NASDAQ:AKBA) initiated with Buy rating and $18 (106% upside) price target by Brean Capital.
    • DexCom (NASDAQ:DXCM) initiated with Neutral rating and $97 (10% upside) price target by B. Riley.
    • vtv Therapeutics (NASDAQ:VTVT) initiated with Buy rating and $13 (82% upside) price target by H.C. Wainwright.
    • ARIAD Pharmaceuticals (NASDAQ:ARIA) initiated with Outperform rating by Leerink Swann.
    • Aldeyra Therapeutics (NASDAQ:ALDX) initiated with Buy rating and $18 (139% upside) price target by H.C. Wainwright.
    • Lantheus Holdings (NASDAQ:LNTH) initiated with Neutral rating and $8 (1% upside) price target by Credit Suisse.
    • BioTime (NYSEMKT:BTX) initiated with Buy rating and $6 (63% upside) price target by Ladenburg.
    • Sanofi (NYSE:SNY) initiated with Neutral rating by Piper Jaffray.
    | Fri, Sep. 30, 7:54 AM
  • Wed, Sep. 28, 8:00 AM
    • ARIAD Pharmaceuticals (NASDAQ:ARIA) announces that partner Otsuka Pharmaceutical Company (OTCPK:OTSKF)(OTCPK:OTSKY) has received marketing approval in Japan for Iclusig (ponatinib) for the treatment of refractory chronic myeloid leukemia and relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
    • The approval triggers a $10M milestone payment to ARIAD from Otsuka pursuant to their December 2014 collaboration agreement.
    • Ponatinib is a multi-targeted tyrosine kinase inhibitor. It was approved in the U.S. for the treatment of two types of leukemia in December 2012.
    • ARIA shares are up 2% premarket on light volume.
    | Wed, Sep. 28, 8:00 AM | 3 Comments